Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses - European Medical Journal

Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses

Oncology
Download PDF

The publication of this infographic was funded by Pierre Fabre Laboratories. It is intended for nurses in countries where neratinib (NERLYNX) is marketed.

Neratinib (NERLYNX®) is indicated for the extended adjuvant treatment of adult patients with early-stage HR+/HER2-overexpressed/amplified breast cancer, who completed adjuvant trastuzumab-based therapy <1 year ago. This infographic offers valuable guidance to nurses in effectively managing neratinib patients to ensure they reap the maximum advantages from this therapy.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given